(isopropylcarbamoylmethyl)carbamic acid benzyl ester | 78639-46-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (isopropylcarbamoylmethyl)carbamic acid benzyl ester
• 英文别名: N-Carbobenzoxyglycin-N-isopropylamid；Benzyl N-[(isopropylcarbamoyl)methyl]carbamate；benzyl N-[2-oxo-2-(propan-2-ylamino)ethyl]carbamate
• CAS: 78639-46-0
• 化学式: C₁₃H₁₈N₂O₃
• mdl: MFCD22421522
• 分子量: 250.298
• InChiKey: IXUOEOAXHYIKHZ-UHFFFAOYSA-N

物化性质

• 熔点：
  96-97 °C
• 沸点：
  466.1±38.0 °C(Predicted)
• 密度：
  1.120±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Benzyl N-[(isopropylcarbamoyl)methyl]carbamate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Benzyl N-[(isopropylcarbamoyl)methyl]carbamate
CAS number: 78639-46-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H18N2O3
Molecular weight: 250.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (isopropylcarbamoylmethyl)carbamic acid benzyl ester 在 10% Pd/C 、 盐酸羟胺 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 、 溶剂黄146 、 乙酸乙酯 、 乙腈 为溶剂， 20.0~87.0 ℃ 、303.99 kPa 条件下， 反应 4.0h， 生成 3-(N-(2-isopropylamino-2-oxoethyl)-N-sulfamoyl)benzamidinium trifluoroacetate
  参考文献：
  名称：

  氨磺酰基苄am对胰蛋白酶，凝血酶和matriptase-2的活性位点作图

  摘要：

  苯甲idine部分是一种众所周知的精氨酸模拟物，已被引入多种配体中，包括胰蛋白酶样丝氨酸蛋白酶的拟肽抑制剂。根据它们的主要底物特异性，苄am残基与此类酶的S1口袋底部的带负电荷的天冬氨酸相互作用。六个系列的苯甲脒衍生物（的1 - 73）的合成和评价作为两个原型丝氨酸蛋白酶的抑制剂，即，牛胰蛋白酶和人凝血酶。作为进一步的靶标，研究了人Matriptase-2（一种最近发现的II型跨膜丝氨酸蛋白酶）。Matriptase-2通过下调铁调素表达在铁稳态中代表了重要的调节蛋白酶。化合物1 –73个分子被设计为包含一个固定的氨磺酰基苯甲酰胺部分作为精氨酸模拟物和一个连接有连接子的附加亚结构，例如叔丁酯，羧酸盐或第二个苯甲idine官能团。用这些抑制剂进行了系统的作图方法，以扫描三种靶蛋白酶的活性位点。特别地，能够与S1和S3 / S4结合位点相互作用的双苯甲m显示出显着的亲和力。在支链bisbenzamidines

  DOI：

  10.1016/j.bmc.2012.08.042
• 作为产物：
  描述：

  异丙胺 在 N-甲基吗啉 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 为溶剂， 反应 16.03h， 以98%的产率得到(isopropylcarbamoylmethyl)carbamic acid benzyl ester
  参考文献：
  名称：

  2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES

  摘要：

  本文披露了式I的2-(1-氧代-1H-异喹啉-2-基)乙酰胺衍生物，或其药用可接受的盐或溶剂，其中每个取代基的定义如规范和索赔中所述。同时披露了包括根据本发明的2-(1-氧代-1H-异喹啉-2-基)乙酰胺衍生物的药物组合物及其在治疗中的应用。

  公开号：

  US20080064678A1

文献信息

• Palladium-Catalyzed β-C–H Arylation of Aliphatic Aldehydes and Ketones Using Amino Amide as a Transient Directing Group
  作者：Cong Dong、Liangfei Wu、Jianwei Yao、Kun Wei

  DOI：10.1021/acs.orglett.9b00366

  日期：2019.4.5

  This paper describes a new amino-amide-based transient directing group (TDG). The TDG can exhibit better performance in the Pd-catalyzed arylation of aliphatic aldehydes and ketones. This reaction showed good substrate compatibility and regioselectivity. The results indicated that 3-amino-N-isopropylpropionamide was more beneficial to the β-arylation of aliphatic aldehydes than other TDGs under relatively

  本文介绍了一个新的基于氨基酰胺的瞬态导向基团（TDG）。TDG在Pd催化的脂族醛和酮的芳基化反应中表现出更好的性能。该反应显示出良好的底物相容性和区域选择性。结果表明，在相对温和的条件下，3-氨基-N-异丙基丙酰胺比其他TDG对脂族醛的β-芳基化更有利。
• Sulfonyl amide inhibitors of calcium channel function
  申请人：Hangeland J. Jon

  公开号：US20050245535A1

  公开（公告）日：2005-11-03

  Compounds of formula I its stereoisomers, solvates, and salts, thereof, wherein: a, b, c, d, f, n, m and Ra are defined herein are are inhibitors of calcium channel function, and are useful in treating calcium channel-dependent disorders, including hypertension.

  化合物I的立体异构体、溶剂合物和盐类，其中：a、b、c、d、f、n、m和Ra的定义如下，是钙通道功能的抑制剂，并且在治疗依赖于钙通道的疾病，包括高血压方面具有用处。
• <i>N</i>-(Benzyloxycarbonyl)glycine Esters and Amides as New Anticonvulsants
  作者：Muriel Geurts、Jacques H. Poupaert、Gerhard K. E. Scriba、Didier M. Lambert

  DOI：10.1021/jm970086f

  日期：1998.1.1

  neutral amino acid exhibiting weak anticonvulsant activities in vivo. Recently, studies have demonstrated that N-(benzyloxycarbonyl)glycine (1) antagonized seizures superior to glycine in addition to activity in the maximal electroshock (MES) test, a convulsive model where glycine is inactive. In the present study a series of ester and amide derivatives of 1 as well as esters of N-(3-phenylpropanoyl)glycine

  甘氨酸是一种小的中性氨基酸，在体内表现出弱的抗惊厥活性。最近，研究表明，在最大电击（MES）测试（一种甘氨酸失活的惊厥模型）中，N-（苄氧羰基）甘氨酸（1）对抗癫痫发作的作用优于甘氨酸。在本研究中，已经制备了一系列的1的酯和酰胺衍生物以及N-（3-苯基丙酰基）甘氨酸的酯（5）。在MES测试以及几种化学诱导的癫痫发作模型中对化合物进行了评估。在所研究的衍生物中，N-（苄氧基羰基）甘氨酸苄酰胺（16）是最有效的化合物，在MES试验中表现出与药物苯妥英相当的抗惊厥活性。腹腔注射后30分钟和3小时测定的中位有效剂量（ED50）为4.8和11.6 mg / kg 行政管理。化合物16还可以在不同的化学诱导模型（例如士的宁，3-巯基丙酸和戊四唑测试）中有效抑制强直性癫痫发作。此外，在150 mg / kg的剂量下，在转子试验中，此处研究的化合物未显示急性神经毒性。结论是，N-（苄氧基羰基）甘氨酸酰胺，特别是16种，是有效的抗惊厥药。
• 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists
  申请人：Letourneau Jeffrey

  公开号：US20080214553A1

  公开（公告）日：2008-09-04

  The present invention relates to 2-(4-oxo4H-quinazolin-3-yl)acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression.

  本发明涉及公式（I）的2-（4-氧代4H-喹唑啉-3-基）乙酰胺衍生物，以及它们作为利尿激素V3拮抗剂的用途，特别是用于治疗抑郁症。
• QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES
  申请人：Letourneau Jeffrey

  公开号：US20080090802A1

  公开（公告）日：2008-04-17

  Disclosed herein are quinazolinone derivatives of formula I, or pharmaceutically acceptable salts or solvates thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions comprising quinazolinone or isoquinolinone according to the present invention and its use in therapy.

  本文披露了式I的喹唑啉衍生物，或其药学上可接受的盐或溶剂，其中每个取代基的定义如规范和要求所述。还披露了包括本发明中的喹唑啉或异喹唑啉的药物组合物及其在治疗中的用途。